Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

Journal of Neurology

Volumn 261, Issue 9, 2014, Pages 1794-1802

  Arnold, Douglas L ^a,b   Gold, Ralf ^c   Kappos, Ludwig ^d   Bar Or, Amit ^b   Giovannoni, Gavin ^e   Selmaj, Krzysztof ^f   Yang, Minhua ^g   Zhang, Ray ^g   Stephan, Monica ^g   Sheikh, Sarah I ^g   Dawson, Katherine T ^g  

^a NEURORX RESEARCH   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g BIOGEN   (United States)

Author keywords

Brain atrophy; Delayed release dimethyl fumarate; Lesion; MRI; Relapsing remitting multiple sclerosis

Indexed keywords

DELAYED RELEASE FORMULATION; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; IMMUNOSUPPRESSIVE AGENT;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; ATROPHY; BRAIN; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ATROPHY; BRAIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939890610     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7412-x     Document Type: Article

References (26)

1. Miller DH, Altmann DR, Chard DT (2012) Advances in imaging to support the development of novel therapies for multiple sclerosis. Clin Pharmacol Ther 91(4):621–634. doi:10.1038/clpt.2011.349
2. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56(4):548–555. doi:10.1002/ana.20224
3. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353(9157):964–969 (pii):S0140673698030530
4. Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68(12):1514–1520. doi:10.1001/archneurol.2011.914
5. Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK (2011) The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler 17(8):949–957. doi:10.1177/1352458511402113
6. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059–2069
7. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125(Pt 8):1676–1695
8. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3):678–692. doi:10.1093/brain/awq386
9. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341(1):274–284. doi:10.1124/jpet.111.190132
10. Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Rocken M (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291–2303. doi:10.1084/jem.20100977
11. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, Hofer E, Wolff K, Petzelbauer P (2002) Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 168(9):4781–4787
12. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107. doi:10.1056/NEJMoa1114287
13. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097. doi:10.1056/NEJMoa1206328
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2001) ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med 47:45–50
15. World Medical Association (2013) Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 8 Jan 2014
16. Francis S (2004) MS lesion analysis on MRI. Department of Neurology & Neurosurgery, McGill University, Montreal
17. Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71(2):136–144. doi:10.1212/01.wnl.0000316810.01120.05
18. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O’Neill GN (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648):1463–1472. doi:10.1016/S0140-6736(08)61619-0
19. Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ (2013) MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol 260(4):1136–1146. doi:10.1007/s00415-012-6775-0
20. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366(11):1000–1009. doi:10.1056/NEJMoa1104318
21. Radue EW, O’Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L (2012) Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 69(10):1259–1269. doi:10.1001/archneurol.2012.1051
22. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O’Neill GN (2012) Effect of BG-12 on contrast-enhanced lesions in patients with relapsing–remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 18(3):314–321. doi:10.1177/1352458511421054
23. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401. doi:10.1056/NEJMoa0909494
24. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910. doi:10.1056/NEJMoa044397
25. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293–1303. doi:10.1056/NEJMoa1014656
26. Fisher E, Barkhof F, van den Elksamp I, Miller M, Jasperse B, Allen R, Kappos L, Rudick R (2009) Comparison of brain atrophy measurement methods in the context of a clinical trial. In: 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Dusseldorf, Germany, 2009